Receptors, Mineralocorticoid

"Receptors, Mineralocorticoid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Cytoplasmic proteins that specifically bind MINERALOCORTICOIDS and mediate their cellular effects. The receptor with its bound ligand acts in the nucleus to induce transcription of specific segments of DNA.

Descriptor ID	D018161
MeSH Number(s)	D12.776.826.750.530
Concept/Terms	Receptors, Mineralocorticoid Receptors, Mineralocorticoid Mineralocorticoid Receptors Receptors, Mineralocorticoids Mineralocorticoids Receptors Mineralocorticoid Receptor Receptor, Mineralocorticoid Receptors, Corticoid Type I Receptors, Corticoid Type I Corticoid Type I Receptors Receptors, Corticoid I Corticoid I Receptors Corticoid I Receptor Receptor, Corticoid I Receptors, Aldosterone Receptors, Aldosterone Aldosterone Receptors Aldosterone Receptor Receptor, Aldosterone

Below are MeSH descriptors whose meaning is more general than "Receptors, Mineralocorticoid".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Receptors, Cytoplasmic and Nuclear [D12.776.826]
Receptors, Steroid [D12.776.826.750]
Receptors, Mineralocorticoid [D12.776.826.750.530]

Below are MeSH descriptors whose meaning is related to "Receptors, Mineralocorticoid".

Below are MeSH descriptors whose meaning is more specific than "Receptors, Mineralocorticoid".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Receptors, Mineralocorticoid" by people in this website by year, and whether "Receptors, Mineralocorticoid" was a major or minor topic of these publications.

Bar chart showing 12 publications over 9 distinct years, with a maximum of 3 publications in 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2008	0	1	1
2011	1	0	1
2013	1	0	1
2014	0	1	1
2018	1	0	1
2020	1	2	3
2021	0	1	1
2022	0	2	2
2025	1	0	1

Below are the most recent publications written about "Receptors, Mineralocorticoid" by people in Profiles.

Wang J, Xu B, Wang Y, Liu J, Wang P, Porche R, Kim S, Yang R, Shao XM, Lutfy K, Liu L, Friedman TC, Jiang M, Liu Y. E-Cigarette Smoke Exposure Elevates Renal MR Expression and Induces BP Elevation. Hypertension. 2025 Sep; 82(9):1492-1504.

View in: PubMed
Ajibade TO, Awodele OA, Tijani MO, Adejumobi OA, Adetona MO, Oyagbemi AA, Adedapo AD, Omobowale TO, Aro AO, Ola-Davies OE, Saba AB, Adedapo AA, Nkadimeng SM, McGaw LJ, Kayoka-Kabongo PN, Oguntibeju OO, Yakubu MA. L-arginine and lisinopril supplementation protects against sodium fluoride-induced nephrotoxicity and hypertension by suppressing mineralocorticoid receptor and angiotensin-converting enzyme 3 activity. Environ Sci Pollut Res Int. 2023 Feb; 30(9):23263-23275.

View in: PubMed
Ajibade T, Akinrinde A, Adetona M, Oyagbemi A, Adedapo A, Larbie C, Omobowale T, Ola-Davies O, Saba A, Adedapo A, Oguntibeju O, Yakubu M. Luteolin normalizes blood pressure via its antioxidant activity and down-regulation of renal Angiotensin II receptor and Mineralocorticoid receptor expressions in rats co-exposed to Diclofenac and sodium fluoride. Niger J Physiol Sci. 2022 Jun 30; 37(1):35-42.

View in: PubMed
Wang Y, Wang J, Yang R, Wang P, Porche R, Kim S, Lutfy K, Liu L, Friedman TC, Jiang M, Liu Y. Decreased 11?-Hydroxysteroid Dehydrogenase Type 2 Expression in the Kidney May Contribute to Nicotine/Smoking-Induced Blood Pressure Elevation in Mice. Hypertension. 2021 06; 77(6):1940-1952.

View in: PubMed
Oyagbemi AA, Bolaji-Alabi FB, Ajibade TO, Adejumobi OA, Ajani OS, Jarikre TA, Omobowale TO, Ola-Davies OE, Soetan KO, Aro AO, Emikpe BO, Saba AB, Adedapo AA, Oyeyemi MO, Nkadimeng SM, Kayoka-Kabongo PN, McGaw LJ, Oguntibeju OO, Yakubu MA. Novel antihypertensive action of rutin is mediated via inhibition of angiotensin converting enzyme/mineralocorticoid receptor/angiotensin 2 type 1 receptor (ATR1) signaling pathways in uninephrectomized hypertensive rats. J Food Biochem. 2020 12; 44(12):e13534.

View in: PubMed
Oyagbemi AA, Omobowale TO, Adejumobi OA, Owolabi AM, Ogunpolu BS, Falayi OO, Hassan FO, Ogunmiluyi IO, Asenuga ER, Ola-Davies OE, Soetan KO, Saba AB, Adedapo AA, Nkadimeng SM, McGaw LJ, Oguntibeju OO, Yakubu MA. Antihypertensive power of Naringenin is mediated via attenuation of mineralocorticoid receptor (MCR)/ angiotensin converting enzyme (ACE)/ kidney injury molecule (Kim-1) signaling pathway. Eur J Pharmacol. 2020 Aug 05; 880:173142.

View in: PubMed
Torres-Rever?n A, Rana M, Gorabi V, Rivera-Lopez LL, Appleyard CB. Short treatment with antalarmin alters adrenal gland receptors in the rat model of endometriosis. PLoS One. 2020; 15(1):e0227456.

View in: PubMed
Valaiyapathi B, Calhoun DA. Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic Syndrome. Curr Hypertens Rep. 2018 03 19; 20(3):23.

View in: PubMed
Judd EK, Calhoun DA, Warnock DG. Pathophysiology and treatment of resistant hypertension: the role of aldosterone and amiloride-sensitive sodium channels. Semin Nephrol. 2014; 34(5):532-9.

View in: PubMed
Guichard JL, Clark D, Calhoun DA, Ahmed MI. Aldosterone receptor antagonists: current perspectives and therapies. Vasc Health Risk Manag. 2013; 9:321-31.

View in: PubMed

People

Explore

Similar Concepts

Top Journals